Literature DB >> 27051716

Multiple cutaneous reticulohistiocytomas successfully treated with topical psoralen plus ultraviolet A therapy combined with intralesional injections of triamcinolone acetonide.

Adam G Harris1, Asri Wijayanti1, Marcia Llewellyn2, Jihan Muhaidat3, Steven Kossard3, Dedee F Murrell1.   

Abstract

Entities:  

Keywords:  PUVA, psoralen combined with ultraviolet A; cutaneous histiocytosis; multiple reticulohistiocytoma; non-Langerhans cell histiocytosis; psoralen plus ultraviolet A therapy; triamcinolone acetonide

Year:  2015        PMID: 27051716      PMCID: PMC4808701          DOI: 10.1016/j.jdcr.2015.03.006

Source DB:  PubMed          Journal:  JAAD Case Rep        ISSN: 2352-5126


× No keyword cloud information.

Introduction

Cutaneous reticulohistiocytosis is a rare form of non-Langerhans cell histiocytosis. Zak originally coined the term reticulohistiocytosis, which is now used to describe the histologic pattern of multinucleate giant cells and oncocytic macrophages showing abundant eosinophilic, finely granular cytoplasm with a ground glass appearance. Clinically, reticulohistiocytomas represent asymptomatic, yellow to red-brown or grey-white papules or nodules, which tend to be solitary. Solitary reticulohistiocytomas are regarded as benign and are found to occur more commonly in young males but with no predilection as to location. Reticulohistiocytomas are rarely reported to occur in crops, then termed multiple reticulohistiocytomas. These crops show no predilection to age, sex, or location and are thought to be benign with the ability to spontaneously regress.4, 5, 6 In contrast, multicentric reticulohistiocytosis is a well-recognized systemic and aggressive form of reticulohistiocytosis, which typically presents in middle-age women with multiple widespread reticulohistiocytomas and associated severe arthritis. This disease can involve multiple organ systems and is usually progressive, necessitating treatment with systemic agents. Unlike solitary or multiple reticulohistiocytoma, multicentric reticulohistiocytosis can represent a paraneoplastic phenomenon, with up to 25% of cases being associated with an underlying internal malignancy.

Case report

We present a 61-year-old white woman of Hungarian background with a 10-month history of a progressive asymptomatic eruption extending from her left clavicle, up the left side of her neck, and including the pre-auricular region. The eruption consisted of multiple erythematous papules and nodules, some of which coalesced to form large plaques localized only to the left side of the neck overlying the sternocleidomastoid muscle (Fig 1). No regional lymphadenopathy was palpable. Her medical history was significant for obesity, type 2 diabetes mellitus, hypertension, hypercholesterolemia, depression, and irritable bowel syndrome. Her regular medications included insulin, amlodipine, and sertraline.
Fig 1

Multiple cutaneous reticulohistiocytomas prior to treatment.

Results of a biopsy showed prominent interstitial epithelioid histiocytes, some showing a ground glass cytoplasm and a patchy lymphohistiocytic infiltrate with few plasma cells (Fig 2). Stains for acid-fast bacilli and fungi were negative. Immunohistochemical stains were positive for CD68, CD163, CD31, and Factor 13a and negative for CD1a, S100, CD34, adipophilin and erythroblast transformation-specific related gene.
Fig 2

Reticulohistiocytoma, repeat skin biopsy. (Hematoxylin-eosin stain; original magnification: ×20.)

Findings for full blood count, serum electrolytes, and liver function tests were all within normal limits. Fasting glucose, cholesterol, and the erythrocyte sedimentation rate were increased, and a small paraprotein of the IgG lambda type was identified in the serum. A bone marrow trephine and aspirate did not show infiltration of histiocytes into the bone marrow, and computed tomography scans of the chest, abdomen, and pelvis showed no lymphadenopathy but did show some degenerative changes in the left hip. On a clinical and histopathologic basis, a diagnosis of multiple cutaneous reticulohistiocytomas was made. Treatment consisted of a series of 3 intralesional injections, each containing 10 mg of a 5-mg/mL solution of triamcinolone acetonide given 3 months apart. Immediately after the second injection she was additionally treated with topical application of 0.01% oxsoralen to the lesions followed by psoralen combined with ultraviolet A (PUVA) therapy 3 times a week for a total of 4 months. At the end of the 10-month treatment regimen, there was a marked reduction in the number, size, and height of the papules and nodules (Fig 3).
Fig 3

Multiple cutaneous reticulohistiocytomas immediately after treatment with 4 months of topical PUVA combined with intralesional injections of triamcinolone acetonide every 3 months for 9 months.

Discussion

The diagnosis and classification of the different types of non-Langerhans cell histiocytoses are ever changing with the development of new immunohistochemical techniques. There is a paucity of documented cases of multiple cutaneous reticulohistiocytomas of the nonmulticentric type and a very limited number presenting high-quality clinical photographs and potential therapeutic strategies to treat the disease. Multiple cutaneous reticulohistiocytomas have been successfully treated surgically and in combination with electrodesiccation. This treatment is favored for solitary lesions but was difficult to justify in our patient because of the associated morbidity of surgery on the head and neck to remove multiple lesions and because the disease is generally regarded as benign with the possibility of spontaneous regression. Topical PUVA therapy has been used successfully in one case of multiple cutaneous reticulohistiocytomas as a noninvasive method of treatment. We used topical PUVA therapy in combination with intralesional injections of triamcinolone acetonide, which led to a significant improvement. We feel the temporality of the improvement fits with a therapeutic response to the described treatment, but spontaneous resolution cannot be ruled out.
  9 in total

1.  Reticulohistiocytoma (solitary epithelioid histiocytoma): a clinicopathologic and immunohistochemical study of 44 cases.

Authors:  Markku Miettinen; John F Fetsch
Journal:  Am J Surg Pathol       Date:  2006-04       Impact factor: 6.394

Review 2.  Multiple cutaneous reticulohistiocytomas (reticulohistiocytic granulomas).

Authors:  M B Toporcer; G R Kantor; A V Benedetto
Journal:  J Am Acad Dermatol       Date:  1991-11       Impact factor: 11.527

Review 3.  Non-Langerhans cell histiocytoses. A new unifying concept.

Authors:  B W Zelger; A Sidoroff; G Orchard; R Cerio
Journal:  Am J Dermatopathol       Date:  1996-10       Impact factor: 1.533

4.  PUVA for diffuse cutaneous reticulohistiocytosis.

Authors:  R S Dawe; H Cameron; J G Lowe
Journal:  Br J Dermatol       Date:  1998-04       Impact factor: 9.302

Review 5.  Multicentric reticulohistiocytosis: a rare yet challenging disease.

Authors:  Arshia D Islam; Stanley M Naguwa; Gurtej S Cheema; John C Hunter; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

6.  Reticulohistiocytoma ("ganglioneuroma") of the skin.

Authors:  F G ZAK
Journal:  Br J Dermatol Syph       Date:  1950-09

7.  Diffuse cutaneous reticulohistiocytosis.

Authors:  D K Goette; R B Odom; J E Fitzwater
Journal:  Arch Dermatol       Date:  1982-03

Review 8.  Malignancy-associated multicentric reticulohistiocytosis: a clinical, histological and immunophenotypic study.

Authors:  J L Snow; S A Muller
Journal:  Br J Dermatol       Date:  1995-07       Impact factor: 9.302

9.  Reticulohistiocytoma and multicentric reticulohistiocytosis. Histopathologic and immunophenotypic distinct entities.

Authors:  B Zelger; R Cerio; H P Soyer; K Misch; G Orchard; E Wilson-Jones
Journal:  Am J Dermatopathol       Date:  1994-12       Impact factor: 1.533

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.